Cymabay Therapeutics, Inc. (CBAY) SEC Filing 8-K Material Event for the period ending Tuesday, March 5, 2019

Cymabay Therapeutics, Inc.

CIK: 1042074 Ticker: CBAY

View differences made from one to another to evaluate Cymabay Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cymabay Therapeutics, Inc..


Assess how Cymabay Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cymabay Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Cymabay Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CBAY
CIK: 1042074
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-065635
Submitted to the SEC: Wed Mar 06 2019 4:33:03 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Tuesday, March 5, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: